Drug
Transmucosal Buprenorphine
Transmucosal Buprenorphine: highest development phase Post-Market, developed by Indivior. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Indivior
Trials
| Drug | Phase | Indication |
|---|---|---|
| Transmucosal Buprenorphine NCT04995029 | Post-Market | Moderate to Severe Opioid-use Disorder |
Latest
No recent events.
Follow Transmucosal Buprenorphine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.